Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Heidi Leister-Tebbe"'
Autor:
Emma Brinkley, Kendall Knuth, Tom Kwon, Christina Mack, Heidi Leister-Tebbe, Weihand Bao, Matthew W Reynolds, Nancy Dreyer
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-5 (2023)
Abstract In January 2021, 999 COVID-19 positive adults in the US enrolled in an online, direct-to-patient registry to describe daily symptom severity and progression over 28 days. The most commonly reported and persistent symptoms were fatigue, heada
Externí odkaz:
https://doaj.org/article/1edf2395e5d44b06ae01d57381828a82
Autor:
Matthew Dryden, Michal Kantecki, Jean Li Yan, Gregory G. Stone, Heidi Leister-Tebbe, Mark Wilcox
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 28, Iss , Pp 108-114 (2022)
ABSTRACT: Objectives: This exploratory pooled analysis assessed the efficacy and safety of ceftaroline fosamil and comparators across six phase III clinical trials in adults with community-acquired pneumonia (CAP) or complicated skin and soft-tissue
Externí odkaz:
https://doaj.org/article/9b91dfa17c6e4c0f8d6a9988707d2d8a
Autor:
Phylinda L.S. Chan, Lynn McFadyen, Andrea Quaye, Heidi Leister‐Tebbe, Victoria M. Hendrick, Jennifer Hammond, Susan Raber
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 6, Pp 551-563 (2021)
Abstract A model‐informed drug development approach was used to select ceftaroline fosamil high‐dose regimens for pediatric patients with complicated skin and soft‐tissue infections caused by Staphylococcus aureus with a ceftaroline minimum inh
Externí odkaz:
https://doaj.org/article/16886efaec0e4d8097a53747c9861115
Autor:
Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, Paula Abreu, Weihang Bao, Wayne Wisemandle, Wajeeha Ansari, Magdalena Alicja Harrington, Jesus Abraham Simón Campos, Kara W Chew, Rienk Pypstra, James M Rusnak
Publikováno v:
Open Forum Infectious Diseases. 9
Background Nirmatrelvir with ritonavir (nirmatrelvir/r) is an oral antiviral COVID-19 treatment. We report its efficacy to shorten time to sustained alleviation and resolution of COVID-19 signs/symptoms in nonhospitalized adults with COVID-19 at high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66f049a90ebd7229311b19c4fd303e7e
https://doi.org/10.1093/ofid/ofac492.994
https://doi.org/10.1093/ofid/ofac492.994
Autor:
Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, Paula Abreu, Weihang Bao, Wayne Wisemandle, Wajeeha Ansari, Jesus Abraham Simón Campos, Rienk Pypstra, James M Rusnak
Publikováno v:
Open Forum Infectious Diseases. 9
Background Nirmatrelvir coadministered with ritonavir (nirmatrelvir/r) is a COVID-19 treatment. This study evaluated nirmatrelvir/r in nonhospitalized, symptomatic adults with COVID-19 at high risk of progressing to severe disease. We report secondar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6ac666c494dd24909b959a3531aab8d
https://doi.org/10.1093/ofid/ofac492.047
https://doi.org/10.1093/ofid/ofac492.047
Autor:
Holly Soares, Mary Lynn Baniecki, Rhonda Cardin, Heidi Leister-Tebbe, Yuao Zhu, Shunjie Guan, Craig Hyde, Wen He, Zhenyu Wang, Li Hao, B. Scott Perrin, Weihang Bao, Phylinda Chan, Bharat Damle, Sandeep Menon, Jennifer Hammond, Annaliesa Anderson
Nirmatrelvir-ritonavir was developed for the treatment of COVID-19 and has shown efficacy in a Phase 2/3 study of high risk patients (EPIC-HR1). Monitoring for the emergence of viral resistance and recurrence of symptoms is a critical component of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89b1f8ec06bf8c5c4f1e60546fee9d66
https://doi.org/10.21203/rs.3.rs-1720472/v2
https://doi.org/10.21203/rs.3.rs-1720472/v2
Autor:
Lynn McFadyen, Jennifer Hammond, Susan Raber, Victoria M Hendrick, Heidi Leister-Tebbe, Andrea Quaye, Phylinda L. S. Chan
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 6, Pp 551-563 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
A model‐informed drug development approach was used to select ceftaroline fosamil high‐dose regimens for pediatric patients with complicated skin and soft‐tissue infections caused by Staphylococcus aureus with a ceftaroline minimum inhibitory c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccf3ebed81cf9fec93c1b632a8576762
https://doi.org/10.1002/psp4.12608
https://doi.org/10.1002/psp4.12608
Autor:
Margaret Tawadrous, Ping Liu, Daniel K. Benjamin, Michael Cohen-Wolkowiez, Heidi Leister-Tebbe, Robert N. Swanson, Susan Raber, Lynn McFadyen, Rujia Xie
Publikováno v:
Clinical Pharmacology and Therapeutics
In a pooled population analysis, we investigated the pharmacokinetics of i.v. anidulafungin in four studies across a full range of adult and pediatric ages in patients with confirmed, suspected, or at high risk of invasive candidiasis (IC). Relations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d80eea8d6d26c01962ecad1a542026a
http://europepmc.org/articles/PMC7485140
http://europepmc.org/articles/PMC7485140
Autor:
Jennifer, Hammond, Heidi, Leister-Tebbe, Annie, Gardner, Paula, Abreu, Weihang, Bao, Wayne, Wisemandle, MaryLynn, Baniecki, Victoria M, Hendrick, Bharat, Damle, Abraham, Simón-Campos, Rienk, Pypstra, James M, Rusnak, Zsolt, Zilahi
Publikováno v:
The New England journal of medicine. 386(15)
Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (MWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f5dc2374b88bfbe99ad58411092b349
https://pubmed.ncbi.nlm.nih.gov/35857648
https://pubmed.ncbi.nlm.nih.gov/35857648
Autor:
Todd Riccobene, Gregory G. Stone, John S. Bradley, Jean Li Yan, Susan Raber, Victoria M Hendrick, Heidi Leister-Tebbe, Veronica Mas Casullo, Phylinda L. S. Chan, Jennifer Hammond
Publikováno v:
The Pediatric infectious disease journal. 39(5)
With increasing antimicrobial resistance, antibiotic treatment options for neonatal late-onset sepsis (LOS) are becoming limited. Primary objective of this study was assessment of the safety of ceftaroline fosamil in LOS.Eligible neonates and very yo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3702bc17b3fb5f695ef849f447480be5
https://pubmed.ncbi.nlm.nih.gov/32091493
https://pubmed.ncbi.nlm.nih.gov/32091493